AFfirm™ RUNX2 Mouse Monoclonal Antibody - #BF8351
Product Info
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Fold/Unfold
Acute myeloid leukemia 3 protein; Alpha subunit 1; AML3; CBF alpha 1; CBF-alpha-1; CBFA1; CCD; CCD1; Cleidocranial dysplasia 1; Core binding factor; Core binding factor runt domain alpha subunit 1; Core binding factor subunit alpha 1; Core-binding factor subunit alpha-1; MGC120022; MGC120023; Oncogene AML 3; Oncogene AML-3; OSF 2; OSF-2; OSF2; Osteoblast specific transcription factor 2; Osteoblast-specific transcription factor 2; OTTHUMP00000016533; PEA2 alpha A; PEA2-alpha A; PEA2aA; PEBP2 alpha A; PEBP2-alpha A; PEBP2A1; PEBP2A2; PEBP2aA; PEBP2aA1; Polyomavirus enhancer binding protein 2 alpha A subunit; Polyomavirus enhancer-binding protein 2 alpha A subunit; Runt domain; Runt related transcription factor 2; Runt-related transcription factor 2; RUNX2; RUNX2_HUMAN; SL3 3 enhancer factor 1 alpha A subunit; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core binding factor alpha A subunit; SL3/AKV core-binding factor alpha A subunit;
Immunogens
A synthesized peptide derived from human RUNX2.
- Q13950 RUNX2_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MASNSLFSTVTPCQQNFFWDPSTSRRFSPPSSSLQPGKMSDVSPVVAAQQQQQQQQQQQQQQQQQQQQQQQEAAAAAAAAAAAAAAAAAVPRLRPPHDNRTMVEIIADHPAELVRTDSPNFLCSVLPSHWRCNKTLPVAFKVVALGEVPDGTVVTVMAGNDENYSAELRNASAVMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKVTVDGPREPRRHRQKLDDSKPSLFSDRLSDLGRIPHPSMRVGVPPQNPRPSLNSAPSPFNPQGQSQITDPRQAQSSPPWSYDQSYPSYLSQMTSPSIHSTTPLSSTRGTGLPAITDVPRRISDDDTATSDFCLWPSTLSKKSQAGASELGPFSDPRQFPSISSLTESRFSNPRMHYPATFTYTPPVTSGMSLGMSATTHYHTYLPPPYPGSSQSQSGPFQTSSTPYLYYGTSSGSYQFPMVPGGDRSPSRMLPPCTTTSNGSTLLNPNLPNQNDGVDADGSHSSSPTVLNSSGRMDESVWRPY
PTMs - Q13950 As Substrate
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| S24 | Phosphorylation | P27361 (MAPK3) | Uniprot |
| S28 | Phosphorylation | P31749 (AKT1) , P27361 (MAPK3) | Uniprot |
| S32 | O-Glycosylation | Uniprot | |
| S33 | O-Glycosylation | Uniprot | |
| S33 | Phosphorylation | Uniprot | |
| S43 | Phosphorylation | P27361 (MAPK3) | Uniprot |
| S118 | Phosphorylation | P45983 (MAPK8) | Uniprot |
| K176 | Ubiquitination | Uniprot | |
| S196 | Phosphorylation | P31749 (AKT1) | Uniprot |
| T198 | Phosphorylation | P31749 (AKT1) | Uniprot |
| T200 | Phosphorylation | P31749 (AKT1) | Uniprot |
| S237 | Phosphorylation | Uniprot | |
| K238 | Acetylation | Uniprot | |
| K238 | Ubiquitination | Uniprot | |
| S247 | Phosphorylation | Uniprot | |
| R258 | Methylation | Uniprot | |
| R267 | Methylation | Uniprot | |
| S275 | Phosphorylation | P27361 (MAPK3) | Uniprot |
| S294 | Phosphorylation | P27361 (MAPK3) | Uniprot |
| S312 | Phosphorylation | P27361 (MAPK3) | Uniprot |
| S314 | Phosphorylation | P27361 (MAPK3) | Uniprot |
| S340 | Phosphorylation | P27361 (MAPK3) | Uniprot |
| S347 | Phosphorylation | Uniprot | |
| S371 | O-Glycosylation | Uniprot | |
| R386 | Methylation | Uniprot | |
| S388 | Phosphorylation | Uniprot | |
| S451 | Phosphorylation | Uniprot | |
| S465 | Phosphorylation | P06493 (CDK1) | Uniprot |
| S480 | Phosphorylation | Uniprot | |
| S499 | Phosphorylation | Uniprot | |
| S503 | Phosphorylation | P27361 (MAPK3) | Uniprot |
| Y521 | Phosphorylation | Uniprot |
Research Backgrounds
Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation.
Phosphorylated; probably by MAP kinases (MAPK). Phosphorylation by HIPK3 is required for the SPEN/MINT and FGF2 transactivation during osteoblastic differentiation (By similarity). Phosphorylation at Ser-451 by CDK1 promotes endothelial cell proliferation required for tumor angiogenesis probably by facilitating cell cycle progression. Isoform 3 is phosphorylated on Ser-340.
Nucleus.
Specifically expressed in osteoblasts.
Heterodimer of an alpha and a beta subunit. The alpha subunit binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Interacts with XRCC6 (Ku70) and XRCC5 (Ku80). Interacts with HIVEP3. Interacts with IFI204. Interaction with SATB2; the interaction results in enhanced DNA binding and transactivation by these transcription factors. Binds to HIPK3. Interacts (isoform 3) with DDX5. Interacts with FOXO1 (via a C-terminal region); the interaction inhibits RUNX2 transcriptional activity towards BGLAP. This interaction is prevented on insulin or IGF1 stimulation as FOXO1 is exported from the nucleus (By similarity). Interacts with CCNB1, KAT6A and KAT6B. Interacts with FOXP3. Interacts with TMEM119 (By similarity). Interacts with OLFM2 (By similarity).
A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes and contains the phosphorylation sites.
Research Fields
· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.